Overview

Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed Conditions

Status:
Completed
Trial end date:
1999-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the single-dose bioequivalence of Par and Oclassen doxycycline monohydrate 100 mg.
Phase:
Phase 1
Details
Lead Sponsor:
Par Pharmaceutical, Inc.
Collaborator:
Anapharm
Treatments:
Doxycycline